Protocol 3: long-term maintenance (for persistent mild symptoms) Goal: Comfortable long-term adherence with minimal GI disruption
Clinical trials show average weight loss of 15% to 21% of body weight over 1218 months with the highest doses
Increasing reports of severe side effects from users of GLP-1 agonist drugs, like Trulicity, have likely driven this rise in cases
Briefly, the development of atherosclerotic lesions requires the action of low-density lipoprotein (LDL), which carries cholesterol through the blood (114)
This article outlines what is currently known about retatrutide's adverse effects, addresses questions around libido and sexual health, and explains when to seek medical advice in the UK context
That is encouraging because it suggests retatrutide may improve body composition without showing a disproportionate lean-mass penalty despite strong weight-loss effects